This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brajtburg, J.
Right arrow Articles by Bolard, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brajtburg, J.
Right arrow Articles by Bolard, J.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, 10 1996, 512-531, Vol 9, No. 4
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Carrier effects on biological activity of amphotericin B

J Brajtburg and J Bolard
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.

Amphotericin B (AmB), the drug of choice for the treatment of most systemic fungal infections, is marketed under the trademark Fungizone, as an AmB-deoxycholate complex suitable for intravenous administration. The association between AmB and deoxycholate is relatively weak; therefore, dissociation occurs in the blood. The drug itself interacts with both mammalian and fungal cell membranes to damage cells, but the greater susceptibility of fungal cells to its effects forms the basis for its clinical usefulness. The ability of the drug to form stable complexes with lipids has allowed the development of new formulations of AmB based on this property. Several lipid-based formulations of the drug which are more selective in damaging fungal or parasitic cells than mammalian cells and some of which also have a better therapeutic index than Fungizone have been developed. In vitro investigations have led to the conclusion that the increase in selectivity observed is due to the selective transfer of AmB from lipid complexes to fungal cells or to the higher thermodynamic stability of lipid formulations. Association with lipids modulates AmB binding to lipoproteins in vivo, thus influencing tissue distribution and toxicity. For example, lipid complexes of AmB can be internalized by macrophages, and the macrophages then serve as a reservoir for the drug. Furthermore, stable AmB-lipid complexes are much less toxic to the host than Fungizone and can therefore be administered in higher doses. Experimentally, the efficacy of AmB-lipid formulations compared with Fungizone depends on the animal model used. Improved therapeutic indices for AmB-lipid formations have been demonstrated in clinical trials, but the definitive trials leading to the selection of an optimal formulation and therapeutic regimen have not been done.


This article has been cited by other articles:

  • Espada, R., Valdespina, S., Dea, M. A., Molero, G., Ballesteros, M. P., Bolas, F., Torrado, J. J. (2008). In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. J Antimicrob Chemother 61: 1125-1131 [Abstract] [Full Text]  
  • Groll, A. H., Lyman, C. A., Petraitis, V., Petraitiene, R., Armstrong, D., Mickiene, D., Alfaro, R. M., Schaufele, R. L., Sein, T., Bacher, J., Walsh, T. J. (2006). Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.. Antimicrob. Agents Chemother. 50: 3418-3423 [Abstract] [Full Text]  
  • Waheed, A. A., Ablan, S. D., Mankowski, M. K., Cummins, J. E., Ptak, R. G., Schaffner, C. P., Freed, E. O. (2006). Inhibition of HIV-1 Replication by Amphotericin B Methyl Ester: SELECTION FOR RESISTANT VARIANTS. J. Biol. Chem. 281: 28699-28711 [Abstract] [Full Text]  
  • Seifert, K., Croft, S. L. (2006). In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs. Antimicrob. Agents Chemother. 50: 73-79 [Abstract] [Full Text]  
  • Al-Mohammed, H. I., Chance, M. L., Bates, P. A. (2005). Production and Characterization of Stable Amphotericin-Resistant Amastigotes and Promastigotes of Leishmania mexicana. Antimicrob. Agents Chemother. 49: 3274-3280 [Abstract] [Full Text]  
  • Lincopan, N., Mamizuka, E. M., Carmona-Ribeiro, A. M. (2005). Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments. J Antimicrob Chemother 55: 727-734 [Abstract] [Full Text]  
  • Falk, R., Hacham, M., Nyska, A., Foley, J. F., Domb, A. J., Polacheck, I. (2005). Induction of interleukin-1{beta}, tumour necrosis factor-{alpha} and apoptosis in mouse organs by amphotericin B is neutralized by conjugation with arabinogalactan. J Antimicrob Chemother 55: 713-720 [Abstract] [Full Text]  
  • Pourshafie, M., Morand, S., Virion, A., Rakotomanga, M., Dupuy, C., Loiseau, P. M. (2004). Cloning of S-Adenosyl-L-Methionine:C-24-{Delta}-Sterol-Methyltransferase (ERG6) from Leishmania donovani and Characterization of mRNAs in Wild-Type and Amphotericin B-Resistant Promastigotes. Antimicrob. Agents Chemother. 48: 2409-2414 [Abstract] [Full Text]  
  • Larabi, M., Pages, N., Pons, F., Appel, M., Gulik, A., Schlatter, J., Bouvet, S., Barratt, G. (2004). Study of the toxicity of a new lipid complex formulation of amphotericin B. J Antimicrob Chemother 53: 81-88 [Abstract] [Full Text]  
  • Larabi, M., Yardley, V., Loiseau, P. M., Appel, M., Legrand, P., Gulik, A., Bories, C., Croft, S. L., Barratt, G. (2003). Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B. Antimicrob. Agents Chemother. 47: 3774-3779 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Petraitis, V., Petraitiene, R., Alfaro, R. M., King, C., Piscitelli, S. C., Walsh, T. J. (2003). Comparative Drug Disposition, Urinary Pharmacokinetics, and Renal Effects of Multilamellar Liposomal Nystatin and Amphotericin B Deoxycholate in Rabbits. Antimicrob. Agents Chemother. 47: 3917-3925 [Abstract] [Full Text]  
  • Cheron, M., Petit, C., Bolard, J., Gaboriau, F. (2003). Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774. J Antimicrob Chemother 52: 904-910 [Abstract] [Full Text]  
  • Lincopan, N., Mamizuka, E. M., Carmona-Ribeiro, A. M. (2003). In vivo activity of a novel amphotericin B formulation with synthetic cationic bilayer fragments. J Antimicrob Chemother 52: 412-418 [Abstract] [Full Text]  
  • Onda, M., Inoue, Y., Kawabata, M., Mita, T. (2003). Susceptibilities of Phospholipid Vesicles Containing Different Sterols to Amphotericin B-Loaded Lysophosphatidylcholine Micelles. J Biochem 134: 121-128 [Abstract] [Full Text]  
  • Larabi, M., Legrand, P., Appel, M., Gil, S., Lepoivre, M., Devissaguet, J.-P., Puisieux, F., Barratt, G. (2001). Reduction of NO Synthase Expression and Tumor Necrosis Factor Alpha Production in Macrophages by Amphotericin B Lipid Carriers. Antimicrob. Agents Chemother. 45: 553-562 [Abstract] [Full Text]  
  • Espuelas, S., Legrand, P., Loiseau, P. M., Bories, C., Barratt, G., Irache, J. M. (2000). In Vitro Reversion of Amphotericin B Resistance in Leishmania donovani by Poloxamer 188. Antimicrob. Agents Chemother. 44: 2190-2192 [Abstract] [Full Text]  
  • Echevarría, I., Barturen, C., Renedo, M. J., Trocóniz, I. F., Dios-Viéitez, M. C. (2000). Comparative Pharmacokinetics, Tissue Distributions, and Effects on Renal Function of Novel Polymeric Formulations of Amphotericin B and Amphotericin B-Deoxycholate in Rats. Antimicrob. Agents Chemother. 44: 898-904 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Werner, K., Petraitiene, R., Petraitis, V., Calendario, M., Field-Ridley, A., Crisp, J., Piscitelli, S. C., Walsh, T. J. (2000). Compartmental Pharmacokinetics and Tissue Distribution of Multilamellar Liposomal Nystatin in Rabbits. Antimicrob. Agents Chemother. 44: 950-957 [Abstract] [Full Text]  
  • Groll, A. H., Mickiene, D., Piscitelli, S. C., Walsh, T. J. (2000). Distribution of Lipid Formulations of Amphotericin B into Bone Marrow and Fat Tissue in Rabbits. Antimicrob. Agents Chemother. 44: 408-410 [Abstract] [Full Text]  
  • Shadkchan, Y., Segal, E. (1999). Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice. J Antimicrob Chemother 44: 787-790 [Abstract] [Full Text]  
  • Falk, R., Domb, A. J., Polacheck, I. (1999). A Novel Injectable Water-Soluble Amphotericin B-Arabinogalactan Conjugate. Antimicrob. Agents Chemother. 43: 1975-1981 [Abstract] [Full Text]  
  • Souza, L. C., Campa, A. (1999). Pharmacological parameters of intravenously administered amphotericin B in rats: comparison of the conventional formulation with amphotericin B associated with a triglyceride-rich emulsion. J Antimicrob Chemother 44: 77-84 [Abstract] [Full Text]  
  • Latge, J.-P. (1999). Aspergillus fumigatus and Aspergillosis. Clin. Microbiol. Rev. 12: 310-350 [Abstract] [Full Text]  
  • Petit, C., Yardley, V., Gaboriau, F., Bolard, J., Croft, S. L. (1999). Activity of a Heat-Induced Reformulation of Amphotericin B Deoxycholate (Fungizone) against Leishmania donovani. Antimicrob. Agents Chemother. 43: 390-392 [Abstract] [Full Text]  
  • Groll, A. H., Gonzalez, C. E., Giri, N., Kligys, K., Love, W., Peter, J., Feuerstein, E., Bacher, J., Piscitelli, S. C., Walsh, T. J. (1999). Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. J Antimicrob Chemother 43: 95-103 [Abstract] [Full Text]  
  • Frankenburg, S., Glick, D., Klaus, S., Barenholz, Y. (1998). Efficacious Topical Treatment for Murine Cutaneous Leishmaniasis with Ethanolic Formulations of Amphotericin B. Antimicrob. Agents Chemother. 42: 3092-3096 [Abstract] [Full Text]  
  • Hossain, M. A., Maesaki, S., Kakeya, H., Noda, T., Yanagihara, K., Sasaki, E., Hirakata, Y., Tomono, K., Tashiro, T., Kohno, S. (1998). Efficacy of NS-718, a Novel Lipid Nanosphere-Encapsulated Amphotericin B, against Cryptococcus neoformans. Antimicrob. Agents Chemother. 42: 1722-1725 [Abstract] [Full Text]  
  • Mbongo, N., Loiseau, P. M., Billion, M. A., Robert-Gero, M. (1998). Mechanism of Amphotericin B Resistance in Leishmania donovani Promastigotes. Antimicrob. Agents Chemother. 42: 352-357 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»